Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 5/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10293499 | 0.99 | NR1I2 (0.37) | NR1I2SCN9AKCNH2CYP3A4SCN5A | |
| SCHEMBL10293502 | 0.94 | PRKCA (0.38) | NR1I2SCN9AKCNH2CYP3A4SCN5A | |
| SCHEMBL13096106 | 0.94 | PRKCA (0.37) | NR1I2SCN9AKCNH2CYP3A4SCN5A | |
| SCHEMBL13096096 | 0.88 | SCN9A (0.35) | NR1I2SCN9AKCNH2CYP3A4SCN5A | |
| SCHEMBL15233632 | 0.88 | NR1I2 (0.34) | NR1I2SCN9AKCNH2CYP3A4SCN5A | |
| SCHEMBL13096090 | 0.87 | MAPT (0.39) | NR1I2SCN9AKCNH2CYP3A4MAPT | |
| SCHEMBL10293517 | 0.87 | NR1I2 (0.37) | NR1I2SCN9AKCNH2CYP3A4SCN5A | |
| SCHEMBL10293526 | 0.87 | MAPT (0.39) | SCN9AKCNH2CYP3A4MAPTCYP2C9 | |
| SCHEMBL13768486 | 0.86 | NR1I2 (0.34) | NR1I2SCN9AKCNH2CYP3A4SCN5A | |
| SCHEMBL13096087 | 0.86 | MAPT (0.34) | NR1I2SCN9AKCNH2CYP3A4SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334282-B2 | Macrocyclic indoles as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-05-10 | — | — | US | disclosed |
| US-9334282-B2 | Macrocyclic indoles as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-05-10 | — | — | US | disclosed |
| US-20130267511-A1 | Macrocyclic Indoles as Hepatitis C Virus Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2013-10-10 | — | — | US | disclosed |
| US-20130267511-A1 | Macrocyclic Indoles as Hepatitis C Virus Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2013-10-10 | — | — | US | disclosed |
| US-8524716-B2 | Macrocyclic indoles as hepatitis C virus inhibitors | JANSSEN R&D IRELAND (IE) | 2013-09-03 | — | — | US | disclosed |
| US-8524716-B2 | Macrocyclic indoles as hepatitis C virus inhibitors | JANSSEN R&D IRELAND (IE) | 2013-09-03 | — | — | US | disclosed |
| US-20100273792-A1 | MACROCYCLIC INDOLES AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. | 2010-10-28 | — | — | US | disclosed |
| US-20100273792-A1 | MACROCYCLIC INDOLES AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. | 2010-10-28 | — | — | US | disclosed |
| WO-2009080836-A2 | MACROCYCLIC INDOLES AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267511-A1 | Macrocyclic Indoles as Hepatitis C Virus Inhibitors | IDO1, HCCS, IDO2 | NR1I2 345/4885SCN9A 3800/4885KCNH2 2137/4885 |
| US-20100273792-A1 | MACROCYCLIC INDOLES AS HEPATITIS C VIRUS INHIBITORS | IDO1, HCCS, IDO2 | NR1I2 345/4885SCN9A 3800/4885KCNH2 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.